JP2011004755A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011004755A5 JP2011004755A5 JP2010176511A JP2010176511A JP2011004755A5 JP 2011004755 A5 JP2011004755 A5 JP 2011004755A5 JP 2010176511 A JP2010176511 A JP 2010176511A JP 2010176511 A JP2010176511 A JP 2010176511A JP 2011004755 A5 JP2011004755 A5 JP 2011004755A5
- Authority
- JP
- Japan
- Prior art keywords
- mva virus
- recombinant mva
- sequence
- homologous
- virus according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241001183012 Modified Vaccinia Ankara virus Species 0.000 claims 36
- 108090000623 proteins and genes Proteins 0.000 claims 12
- 210000004027 cell Anatomy 0.000 claims 9
- 238000000034 method Methods 0.000 claims 7
- 239000013598 vector Substances 0.000 claims 7
- 238000003780 insertion Methods 0.000 claims 5
- 230000037431 insertion Effects 0.000 claims 5
- 241001465754 Metazoa Species 0.000 claims 4
- 241000700605 Viruses Species 0.000 claims 4
- 230000028993 immune response Effects 0.000 claims 4
- 108091033319 polynucleotide Proteins 0.000 claims 4
- 102000040430 polynucleotide Human genes 0.000 claims 4
- 239000002157 polynucleotide Substances 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 229960005486 vaccine Drugs 0.000 claims 3
- 241000710831 Flavivirus Species 0.000 claims 2
- 230000010354 integration Effects 0.000 claims 2
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 claims 2
- 230000003612 virological effect Effects 0.000 claims 2
- 108020001019 DNA Primers Proteins 0.000 claims 1
- 239000003155 DNA primer Substances 0.000 claims 1
- 241000725619 Dengue virus Species 0.000 claims 1
- 108091029795 Intergenic region Proteins 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 241000700618 Vaccinia virus Species 0.000 claims 1
- 206010046865 Vaccinia virus infection Diseases 0.000 claims 1
- 108020005202 Viral DNA Proteins 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000005260 human cell Anatomy 0.000 claims 1
- 238000010348 incorporation Methods 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000013615 primer Substances 0.000 claims 1
- 208000007089 vaccinia Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200200752 | 2002-05-16 | ||
| DKPA200200753 | 2002-05-16 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004506501A Division JP4693092B2 (ja) | 2002-05-16 | 2003-05-14 | ポックスウイルスゲノムに挿入された相同遺伝子を発現させる組換えポックスウイルス |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011004755A JP2011004755A (ja) | 2011-01-13 |
| JP2011004755A5 true JP2011004755A5 (enExample) | 2011-07-28 |
Family
ID=29551228
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004506500A Expired - Lifetime JP4895505B2 (ja) | 2002-05-16 | 2003-05-14 | 変異ワクシニアウイルスアンカラ（ｍｖａ）ゲノム中の挿入部位としての遺伝子間領域 |
| JP2004506501A Expired - Lifetime JP4693092B2 (ja) | 2002-05-16 | 2003-05-14 | ポックスウイルスゲノムに挿入された相同遺伝子を発現させる組換えポックスウイルス |
| JP2010176511A Pending JP2011004755A (ja) | 2002-05-16 | 2010-08-05 | ポックスウイルスゲノムに挿入された相同遺伝子を発現させる組換えポックスウイルス |
| JP2010176512A Expired - Lifetime JP5777199B2 (ja) | 2002-05-16 | 2010-08-05 | ポックスウイルスゲノムに挿入された相同遺伝子を発現させる組換えポックスウイルス |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004506500A Expired - Lifetime JP4895505B2 (ja) | 2002-05-16 | 2003-05-14 | 変異ワクシニアウイルスアンカラ（ｍｖａ）ゲノム中の挿入部位としての遺伝子間領域 |
| JP2004506501A Expired - Lifetime JP4693092B2 (ja) | 2002-05-16 | 2003-05-14 | ポックスウイルスゲノムに挿入された相同遺伝子を発現させる組換えポックスウイルス |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010176512A Expired - Lifetime JP5777199B2 (ja) | 2002-05-16 | 2010-08-05 | ポックスウイルスゲノムに挿入された相同遺伝子を発現させる組換えポックスウイルス |
Country Status (22)
| Country | Link |
|---|---|
| US (14) | US7550147B2 (enExample) |
| EP (3) | EP2253709B1 (enExample) |
| JP (4) | JP4895505B2 (enExample) |
| KR (4) | KR101041691B1 (enExample) |
| CN (6) | CN1653183B (enExample) |
| AT (1) | ATE315660T1 (enExample) |
| AU (4) | AU2003236646B2 (enExample) |
| BR (2) | BRPI0311178B8 (enExample) |
| CA (3) | CA2481799C (enExample) |
| DE (1) | DE60303218T2 (enExample) |
| DK (2) | DK1506301T3 (enExample) |
| EA (3) | EA007811B1 (enExample) |
| ES (1) | ES2256776T3 (enExample) |
| IL (4) | IL164177A0 (enExample) |
| MX (2) | MXPA04010713A (enExample) |
| NO (3) | NO334273B1 (enExample) |
| NZ (2) | NZ536502A (enExample) |
| PL (2) | PL218318B1 (enExample) |
| PT (1) | PT1407033E (enExample) |
| SI (1) | SI1407033T1 (enExample) |
| UA (1) | UA82479C2 (enExample) |
| WO (2) | WO2003097845A1 (enExample) |
Families Citing this family (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4101327C1 (enExample) * | 1991-01-18 | 1991-10-24 | Mercedes-Benz Aktiengesellschaft, 7000 Stuttgart, De | |
| HU230198B1 (hu) * | 2000-11-23 | 2015-10-28 | Bavarian Nordic A/S | Módosított Vacciniavírus Ankara-variáns |
| EP1420822B2 (en) * | 2002-04-19 | 2017-07-05 | Bavarian Nordic A/S | Modified vaccinia virus ankara for the vaccination of neonates |
| US7501127B2 (en) * | 2002-05-16 | 2009-03-10 | Bavarian Nordic A/S | Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara |
| UA82479C2 (uk) | 2002-05-16 | 2008-04-25 | Бавариан Нордика А/С | Міжгенні регіони як сайти вставки в геном модифікованого вірусу коров'ячої віспи ankara (mva) |
| AU2003264144C1 (en) * | 2002-09-05 | 2009-12-17 | Bavarian Nordic A/S | Method for the cultivation of primary cells and for the amplification of viruses under serum free conditions |
| JP5052893B2 (ja) * | 2003-02-20 | 2012-10-17 | アメリカ合衆国 | ポックスベクターにおける新規の挿入部位 |
| GB2402391A (en) * | 2003-06-04 | 2004-12-08 | Oxxon Pharmaccines Ltd | Fowlpox recombinant genome |
| US7951576B2 (en) * | 2004-11-05 | 2011-05-31 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods for preparing cells and viruses |
| CN101128217B (zh) * | 2005-02-23 | 2012-04-25 | 巴法里安诺迪克有限公司 | 改良的痘病毒快速诱导抗痘病毒或其它传染物的免疫力的用途 |
| CA2651456A1 (en) * | 2006-05-19 | 2007-11-29 | Glycofi, Inc. | Recombinant vectors |
| DK2402451T3 (en) * | 2006-08-25 | 2018-06-25 | The Government Of The Us Secretary Department Of Health And Human Services | Method for Stabilizing a DNA Insert in a Recombinant Vaccine Vector |
| EP2415783B1 (en) | 2006-10-16 | 2016-12-14 | Genelux Corporation | Modified vaccinia virus strains for use in a diagnostic and therapeutic method |
| US8440202B2 (en) * | 2006-11-09 | 2013-05-14 | The United States Of America As Represented By The Secretary Of The Navy | Induction of an immune response against dengue virus using the prime-boost approach |
| WO2008127307A2 (en) * | 2006-11-09 | 2008-10-23 | The United States Of America As Represented By The Secretary Of The Navy | Induction of an immune response against dengue virus using prime-boost approach |
| CL2008000249A1 (es) * | 2007-01-30 | 2008-05-30 | Transgene Sa | Uso de una molecula de acido nucleico que codifica al menos un polipeptido e2 del papilomavirus, un vector o una particula virica infecciosa que la comprenda para tratar una infeccion permanente por papilomavirus causada por al menos un papilomavirus |
| US8268327B2 (en) | 2007-04-27 | 2012-09-18 | Bavarian Nordic A/S | Immediate protection against pathogens via MVA |
| KR101514473B1 (ko) * | 2007-05-15 | 2015-04-22 | 트랜스진 에스.에이. | 다중 유전자 발현용 벡터 |
| EP2155883A1 (en) * | 2007-05-30 | 2010-02-24 | Wyeth LLC | Raccoon poxvirus expressing genes of feline antigens |
| TW200907058A (en) * | 2007-05-30 | 2009-02-16 | Wyeth Corp | Raccoon poxvirus expressing rabies glycoproteins |
| ES2608604T3 (es) | 2007-10-18 | 2017-04-12 | Bavarian Nordic A/S | Uso de MVA para tratar el cáncer de próstata |
| US20110052627A1 (en) * | 2008-06-20 | 2011-03-03 | Paul Chaplin | Recombinant modified vaccinia virus measles vaccine |
| KR100894430B1 (ko) * | 2008-11-11 | 2009-04-22 | 시스템디엔디(주) | 초음파, 음향 및 온도변화를 이용한 밸브의 유체누설 측정장치 및 이를 이용한 유체누설 측정방법 |
| EP2352834B1 (en) * | 2008-11-21 | 2016-12-21 | Bavarian Nordic A/S | Vector comprising multiple homologous nucleotide sequences |
| US8580276B2 (en) | 2009-06-05 | 2013-11-12 | City Of Hope | Genetically stable recombinant modified vaccinia ankara (rMVA) vaccines and methods of preparation thereof |
| JP2013507107A (ja) | 2009-10-08 | 2013-03-04 | バヴァリアン・ノルディック・アクティーゼルスカブ | Ｈｉｖに対するヒトにおける広範なｔ細胞応答の生成 |
| WO2011047324A1 (en) | 2009-10-16 | 2011-04-21 | The U.S.A. As Represented By The Secretary , Department Of Health And Human Services . | Recombinant modified vaccinia ankara (mva) vaccinia virus containing restructured insertion sites |
| WO2011087839A1 (en) | 2009-12-22 | 2011-07-21 | Baxter International Inc. | Vaccine to influenza a virus |
| CN103118709A (zh) * | 2010-03-26 | 2013-05-22 | 新兴产品开发盖瑟斯堡有限公司 | 流感病毒基质2蛋白的胞外域、其表达系统和应用 |
| CA2802430C (en) | 2010-07-20 | 2021-07-20 | Bavarian Nordic A/S | Method for harvesting poxvirus |
| AU2011305348A1 (en) * | 2010-09-23 | 2013-04-18 | Baxter Healthcare Sa | Recombinant viral vectors and methods for inducing an immune response to yellow fever virus |
| US9173933B2 (en) | 2010-10-15 | 2015-11-03 | Bavarian Nordic A/S | Recombinant modified vaccinia virus Ankara influenza vaccine |
| EP2697368B1 (en) | 2011-04-15 | 2019-06-05 | Genelux Corporation | Clonal strains of attenuated vaccinia viruses and methods of use thereof |
| WO2013083254A1 (en) | 2011-12-09 | 2013-06-13 | Bavarian Nordic A/S | Poxvirus vector for the expression of bacterial antigens linked to tetanus toxin fragment c |
| EP2620446A1 (en) | 2012-01-27 | 2013-07-31 | Laboratorios Del Dr. Esteve, S.A. | Immunogens for HIV vaccination |
| HK1203358A1 (en) | 2012-06-05 | 2015-10-30 | The Australian National University | Vaccination with interleukin-4 antagonists |
| SI2879702T1 (sl) | 2012-08-01 | 2020-02-28 | Bavarian Nordic A/S | Cepivo na osnovi rekombinantnega modificiranega virusa vakcinacije Ankara (MVA) proti respiratornemu sincitialnemu virusu (RSV) |
| WO2014043535A1 (en) | 2012-09-14 | 2014-03-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compositions for the treatment of cancer |
| WO2014055960A1 (en) | 2012-10-05 | 2014-04-10 | Genelux Corporation | Energy absorbing-based diagnostic and therapeutic methods employing nucleic acid molecules encoding chromophore-producing enzymes |
| EP2908851A1 (en) | 2012-10-19 | 2015-08-26 | Bavarian Nordic Inc. | Methods and compositions for the treatment of cancer |
| EP2968528B1 (en) * | 2013-03-15 | 2022-02-23 | Sementis Limited | Immune modulation |
| DE102013004595A1 (de) | 2013-03-15 | 2014-09-18 | Emergent Product Development Germany Gmbh | RSV-Impfstoffe |
| WO2014139587A1 (en) * | 2013-03-15 | 2014-09-18 | Okairòs Ag | Improved poxviral vaccines |
| WO2015103438A2 (en) | 2014-01-02 | 2015-07-09 | Genelux Corporation | Oncolytic virus adjunct therapy with agents that increase virus infectivity |
| KR101623498B1 (ko) | 2014-10-16 | 2016-05-24 | 대한민국 | 약독화 백시니아 바이러스주 kvac１０３ |
| KR101645642B1 (ko) | 2014-10-16 | 2016-08-11 | 대한민국 | Kvac１０３ 유래의 재조합 백시니아 바이러스 |
| EP4122492A1 (en) | 2015-02-25 | 2023-01-25 | Memorial Sloan Kettering Cancer Center | Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors |
| KR20180006916A (ko) | 2015-04-17 | 2018-01-19 | 메모리얼 슬로안-케터링 캔서 센터 | 고형 종양에 대한 면역치료제로서 mva 또는 mva델타e3l의 용도 |
| KR20160140075A (ko) * | 2015-05-29 | 2016-12-07 | 코오롱생명과학 주식회사 | 폭스바이러스 유래 프로모터 및 이를 포함하는 벡터 |
| US11103570B2 (en) * | 2015-06-15 | 2021-08-31 | Bavarian Nordic A/S | Recombinant modified vaccinia virus Ankara (MVA) foot and mouth disease virus (FMDV) vaccine |
| FR3042121A1 (fr) | 2015-10-08 | 2017-04-14 | Jean-Marc Limacher | Composition anti-tumorale |
| CN106591361A (zh) * | 2015-10-20 | 2017-04-26 | 钱文斌 | 一种重组痘溶瘤病毒及其构建方法和应用 |
| CN109071592B (zh) | 2016-01-08 | 2022-07-19 | 吉奥瓦科斯公司 | 用于产生对肿瘤相关抗原的免疫应答的组合物和方法 |
| WO2017129765A1 (en) | 2016-01-29 | 2017-08-03 | Bavarian Nordic A/S | Recombinant modified vaccinia virus ankara (mva) equine encephalitis virus vaccine |
| US20190030157A1 (en) * | 2016-02-03 | 2019-01-31 | Geovax Inc. | Compositions and Methods for Generating an Immune Response to a Flavivirus |
| CN109152815B (zh) | 2016-02-25 | 2022-10-18 | 纪念斯隆凯特琳癌症中心 | 用于癌症免疫治疗的具有胸苷激酶缺失和具有或不具有人flt3l或gm-csf表达的复制型减毒痘苗病毒 |
| WO2017147554A2 (en) | 2016-02-25 | 2017-08-31 | Memorial Sloan-Kettering Cancer Center | Recombinant mva or mvadele3l expressing human flt3l and use thereof as immuno-therapeutic agents against solid tumors |
| EP3452087A1 (en) | 2016-05-02 | 2019-03-13 | Janssen Vaccines & Prevention B.V. | Therapeutic hpv vaccine combinations |
| MY200887A (en) * | 2016-08-19 | 2024-01-22 | Sementis Ltd | Viral Vaccines |
| EP3518656A4 (en) * | 2016-09-30 | 2020-09-30 | Monsanto Technology LLC | PROCESS FOR SELECTING TARGET SITES FOR MODIFICATION OF SITE-SPECIFIC GENOME IN PLANTS |
| CN111107872A (zh) | 2017-05-12 | 2020-05-05 | 纪念斯隆-凯特林癌症中心 | 有用于癌症免疫疗法的牛痘病毒突变体 |
| BR112019026126A2 (pt) * | 2017-06-15 | 2020-06-30 | Janssen Vaccines & Prevention B.V. | vetores de poxvírus que codificam antígenos do hiv e métodos de uso dos mesmos |
| US11311612B2 (en) | 2017-09-19 | 2022-04-26 | Geovax, Inc. | Compositions and methods for generating an immune response to treat or prevent malaria |
| WO2019217922A1 (en) | 2018-05-11 | 2019-11-14 | City Of Hope | Genetically modified recombinant vaccinia ankara (rmva) vaccines of improved stability and methods of preparation thereof |
| CN112512569A (zh) * | 2018-05-11 | 2021-03-16 | 希望之城 | 表达多个巨细胞病毒(cmv)抗原的mva载体及其用途 |
| CA3112654A1 (en) | 2018-09-15 | 2020-03-19 | Memorial Sloan Kettering Cancer Center | Recombinant poxviruses for cancer immunotherapy |
| CN113924114A (zh) | 2019-05-22 | 2022-01-11 | 吉利德科学公司 | Tlr7调节化合物和hiv疫苗的组合 |
| CN111979204B (zh) * | 2019-05-24 | 2023-10-13 | 杭州功楚生物科技有限公司 | 携带海绵凝集素基因的溶瘤痘苗病毒、构建方法及用途 |
| AU2020384323A1 (en) | 2019-11-14 | 2022-06-02 | Aelix Therapeutics, S.L. | Dosage regimens for vaccines |
| EP3842065A1 (en) * | 2019-12-23 | 2021-06-30 | Transgene | Process for designing a recombinant poxvirus for a therapeutic vaccine |
| CA3167052A1 (en) | 2020-02-14 | 2021-08-19 | Mary Jo Hauser | Vaccines and uses thereof to induce an immune response to sars-cov2 |
| TW202203966A (zh) * | 2020-03-31 | 2022-02-01 | 澳大利亞商賽門蒂斯公司 | 用於防範ｃｏｖｉｄ－１９之以減毒的痘病毒載體為底質之疫苗 |
| BR112023015467A2 (pt) | 2021-02-02 | 2023-10-10 | Geovax Inc | Vetor viral de vaccinia ankara recombinante modificado, métodos para aumentar uma resposta imunológica a um antígeno alvo em um paciente e para prevenir, tratar ou induzir uma resposta imunológica contra um antígeno alvo, e, composição farmacêutica |
| EP4551240A1 (en) | 2022-07-08 | 2025-05-14 | Viromissile, Inc. | Oncolytic vaccinia viruses and recombinant viruses and methods of use thereof |
| FR3160186A1 (fr) | 2024-03-13 | 2025-09-19 | Odimma Therapeutics | Vecteur non-viral pour transcription augmentee |
| FR3171450A1 (fr) | 2025-01-17 | 2026-07-24 | Odimma Therapeutics | Virus enveloppé pour la transfection d’acides nucléiques exogènes. |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5338683A (en) * | 1981-12-24 | 1994-08-16 | Health Research Incorporated | Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins |
| JPH0795956B2 (ja) * | 1986-09-22 | 1995-10-18 | 京都大学長 | ポックスウイルス由来発現制御領域 |
| US5093258A (en) * | 1988-08-26 | 1992-03-03 | Therion Biologics Corporation | Recombinant fowlpox virus and recombination vector |
| US5225336A (en) * | 1989-03-08 | 1993-07-06 | Health Research Incorporated | Recombinant poxvirus host range selection system |
| US5651972A (en) | 1989-04-21 | 1997-07-29 | University Of Florida Research Foundation, Inc. | Use of recombinant swine poxvirus as a live vaccine vector |
| MY109299A (en) * | 1990-08-15 | 1996-12-31 | Virogenetics Corp | Recombinant pox virus encoding flaviviral structural proteins |
| US5514375A (en) | 1990-08-15 | 1996-05-07 | Virogenetics Corporation | Flavivirus recombinant poxvirus vaccine |
| US6893845B1 (en) * | 1990-09-28 | 2005-05-17 | Applied Molecular Evolution, Inc. | Surface expression libraries of heteromeric receptors |
| EP0575491B1 (en) * | 1991-03-07 | 2003-08-13 | Virogenetics Corporation | Genetically engineered vaccine strain |
| BE1004877A3 (fr) * | 1991-05-27 | 1993-02-16 | Solvay | Virus de l'avipox recombinant, culture de cellules infectees par ce virus et vaccins pour la volaille derives de ce virus. |
| FR2679249B1 (fr) * | 1991-07-15 | 1993-11-26 | Centre Nal Recherc Scientifique | Souches de levure avec integration stable de genes heterologues. |
| CA2110505A1 (en) | 1991-07-26 | 1993-02-18 | Enzo Paoletti | Infectious bursal disease virus recombinant poxvirus vaccine |
| EP1380651A2 (en) * | 1991-08-26 | 2004-01-14 | Baxter Healthcare S.A. | Recombinant fowlpox virus with intact FPV-tk-gene |
| ATE181108T1 (de) * | 1991-08-26 | 1999-06-15 | Immuno Ag | Direkt molekuläre klonierung eines modifizierten genoms eines chordopocken-virus |
| US5676950A (en) | 1994-10-28 | 1997-10-14 | University Of Florida | Enterically administered recombinant poxvirus vaccines |
| UA68327C2 (en) * | 1995-07-04 | 2004-08-16 | Gsf Forschungszentrum Fur Unwe | A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals |
| EP0753581A1 (en) * | 1995-07-10 | 1997-01-15 | Immuno Ag | Improved recombinant eukaryotic cytoplasmic viruses, method for their production and their use as vaccines |
| DE19629828A1 (de) * | 1996-07-24 | 1998-01-29 | Bayer Ag | Carbanilide |
| ID19548A (id) * | 1996-09-24 | 1998-07-23 | Bavarian Nordic Res Inst As | Virus mva rekombinan yang mengekspresikan antigen-antigen virus demam dan penggunaan daripadanya dalam vaksin-vaksin |
| AUPP380598A0 (en) * | 1998-05-29 | 1998-06-25 | Commonwealth Scientific And Industrial Research Organisation | Genetically manipulated entomopoxvirus |
| US6252871B1 (en) | 1998-07-01 | 2001-06-26 | Powerwave Technologies, Inc. | Switchable combiner/splitter |
| US20040265324A1 (en) * | 1999-03-23 | 2004-12-30 | Cardosa Mary Jane | Recombinant MVA virus expressing dengue virus antigens, and the use thereof in vaccines |
| WO2000073476A1 (en) * | 1999-05-28 | 2000-12-07 | Gsf Forschungszentrum Für Umwelt Und Gesundheit Gmbh | Vector for integration of heterologous sequences into poxviral genomes |
| KR100880765B1 (ko) * | 2000-03-14 | 2009-02-02 | 버베리안 노딕 에이/에스 | 변형된 백시니아 바이러스 안카라(ｍｖａ)의 변형 균주 |
| CA2341356C (en) * | 2000-04-14 | 2011-10-11 | Transgene S.A. | Poxvirus with targeted infection specificity |
| EP1326990B1 (en) * | 2000-08-29 | 2007-09-19 | Wyeth Holdings Corporation | Packaging of positive-strand rna virus replicon particles |
| HU230198B1 (hu) | 2000-11-23 | 2015-10-28 | Bavarian Nordic A/S | Módosított Vacciniavírus Ankara-variáns |
| UA82479C2 (uk) | 2002-05-16 | 2008-04-25 | Бавариан Нордика А/С | Міжгенні регіони як сайти вставки в геном модифікованого вірусу коров'ячої віспи ankara (mva) |
| US7501127B2 (en) | 2002-05-16 | 2009-03-10 | Bavarian Nordic A/S | Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara |
| ATE365220T1 (de) * | 2002-11-25 | 2007-07-15 | Bavarian Nordic As | Mindestens zwei ati promotoren enthaltendes rekombinantes pockenvirus |
-
2003
- 2003-05-14 UA UA20041109409A patent/UA82479C2/uk unknown
- 2003-05-14 CN CN038111063A patent/CN1653183B/zh not_active Expired - Lifetime
- 2003-05-14 JP JP2004506500A patent/JP4895505B2/ja not_active Expired - Lifetime
- 2003-05-14 KR KR1020047018165A patent/KR101041691B1/ko not_active Expired - Lifetime
- 2003-05-14 SI SI200330215T patent/SI1407033T1/sl unknown
- 2003-05-14 US US10/514,761 patent/US7550147B2/en not_active Expired - Lifetime
- 2003-05-14 AT AT03752741T patent/ATE315660T1/de active
- 2003-05-14 NZ NZ536502A patent/NZ536502A/en not_active IP Right Cessation
- 2003-05-14 MX MXPA04010713A patent/MXPA04010713A/es active IP Right Grant
- 2003-05-14 EA EA200401507A patent/EA007811B1/ru not_active IP Right Cessation
- 2003-05-14 DE DE2003603218 patent/DE60303218T2/de not_active Expired - Lifetime
- 2003-05-14 DK DK03735384T patent/DK1506301T3/da active
- 2003-05-14 EA EA200401506A patent/EA012160B1/ru not_active IP Right Cessation
- 2003-05-14 MX MXPA04011194A patent/MXPA04011194A/es active IP Right Grant
- 2003-05-14 EA EA200900180A patent/EA020230B1/ru not_active IP Right Cessation
- 2003-05-14 ES ES03752741T patent/ES2256776T3/es not_active Expired - Lifetime
- 2003-05-14 PL PL372088A patent/PL218318B1/pl unknown
- 2003-05-14 CN CN2012101928085A patent/CN102703393A/zh active Pending
- 2003-05-14 JP JP2004506501A patent/JP4693092B2/ja not_active Expired - Lifetime
- 2003-05-14 NZ NZ536501A patent/NZ536501A/en not_active IP Right Cessation
- 2003-05-14 BR BRPI0311178A patent/BRPI0311178B8/pt not_active IP Right Cessation
- 2003-05-14 US US10/510,189 patent/US7338662B2/en not_active Expired - Lifetime
- 2003-05-14 IL IL16417703A patent/IL164177A0/xx active IP Right Grant
- 2003-05-14 CN CN200910208520A patent/CN101831411A/zh active Pending
- 2003-05-14 CN CN2012101926963A patent/CN102719408A/zh active Pending
- 2003-05-14 KR KR1020107021891A patent/KR101138067B1/ko not_active Expired - Lifetime
- 2003-05-14 PT PT03752741T patent/PT1407033E/pt unknown
- 2003-05-14 EP EP10008120.7A patent/EP2253709B1/en not_active Expired - Lifetime
- 2003-05-14 DK DK03752741T patent/DK1407033T3/da active
- 2003-05-14 EP EP20030752741 patent/EP1407033B1/en not_active Expired - Lifetime
- 2003-05-14 AU AU2003236646A patent/AU2003236646B2/en not_active Expired
- 2003-05-14 WO PCT/EP2003/005045 patent/WO2003097845A1/en not_active Ceased
- 2003-05-14 KR KR1020117031095A patent/KR20120002627A/ko not_active Withdrawn
- 2003-05-14 CA CA2481799A patent/CA2481799C/en not_active Expired - Lifetime
- 2003-05-14 KR KR1020047018293A patent/KR101005630B1/ko not_active Expired - Lifetime
- 2003-05-14 AU AU2003242540A patent/AU2003242540A1/en not_active Abandoned
- 2003-05-14 PL PL372093A patent/PL216760B1/pl unknown
- 2003-05-14 CN CNB038111225A patent/CN100494388C/zh not_active Expired - Lifetime
- 2003-05-14 EP EP20030735384 patent/EP1506301B1/en not_active Expired - Lifetime
- 2003-05-14 CA CA 2812019 patent/CA2812019A1/en not_active Abandoned
- 2003-05-14 CN CN2011100588236A patent/CN102199628A/zh active Pending
- 2003-05-14 IL IL16417203A patent/IL164172A0/xx unknown
- 2003-05-14 CA CA2481521A patent/CA2481521C/en not_active Expired - Lifetime
- 2003-05-14 BR BR0310051A patent/BR0310051A/pt not_active IP Right Cessation
- 2003-05-14 WO PCT/EP2003/005047 patent/WO2003097846A1/en not_active Ceased
-
2004
- 2004-11-12 NO NO20044940A patent/NO334273B1/no not_active IP Right Cessation
- 2004-12-16 NO NO20045480A patent/NO336489B1/no not_active IP Right Cessation
-
2007
- 2007-11-15 US US11/985,510 patent/US9109233B2/en active Active
-
2008
- 2008-07-28 IL IL19308808A patent/IL193088A/en active IP Right Grant
- 2008-07-28 IL IL193087A patent/IL193087A/en active IP Right Grant
- 2008-12-09 AU AU2008255213A patent/AU2008255213B2/en not_active Expired
- 2008-12-19 US US12/339,743 patent/US20100173388A1/en not_active Abandoned
-
2009
- 2009-02-03 AU AU2009200380A patent/AU2009200380C1/en not_active Expired
- 2009-05-19 US US12/468,120 patent/US7964374B2/en not_active Expired - Lifetime
- 2009-05-19 US US12/468,127 patent/US8034354B2/en not_active Expired - Lifetime
-
2010
- 2010-08-05 JP JP2010176511A patent/JP2011004755A/ja active Pending
- 2010-08-05 JP JP2010176512A patent/JP5777199B2/ja not_active Expired - Lifetime
- 2010-09-30 US US12/894,589 patent/US20110053260A1/en not_active Abandoned
- 2010-09-30 US US12/894,550 patent/US20110053259A1/en not_active Abandoned
-
2011
- 2011-04-15 US US13/087,715 patent/US8288125B2/en not_active Expired - Fee Related
- 2011-04-15 US US13/087,649 patent/US8309326B2/en not_active Expired - Fee Related
- 2011-09-15 US US13/233,329 patent/US8414900B2/en not_active Expired - Fee Related
- 2011-09-16 US US13/234,230 patent/US8435543B2/en not_active Expired - Fee Related
- 2011-09-29 NO NO20111324A patent/NO20111324A1/no not_active Application Discontinuation
-
2012
- 2012-02-13 US US13/371,580 patent/US20120178157A1/en not_active Abandoned
-
2013
- 2013-05-02 US US13/886,093 patent/US8741308B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010259446A5 (enExample) | ||
| KR102135818B1 (ko) | 강력한 ｔ-세포 및 항체 반응을 위한 ｐｒ13.5 프로모터 | |
| JP4693092B2 (ja) | ポックスウイルスゲノムに挿入された相同遺伝子を発現させる組換えポックスウイルス | |
| Lasaro et al. | New insights on adenovirus as vaccine vectors | |
| US20200368333A1 (en) | Cmv vectors comprising microrna recognition elements | |
| Alharbi | Poxviral promoters for improving the immunogenicity of MVA delivered vaccines | |
| JP2013507935A5 (enExample) | ||
| EP2558581A1 (en) | Poxvirus expression system | |
| CN104894075A (zh) | CRISPR/Cas9和Cre/lox系统编辑伪狂犬病毒基因组制备疫苗方法和应用 | |
| RU2013152648A (ru) | Аденовирус обезьян и гибридные аденовирусные векторы | |
| WO2008142479A3 (en) | Intergenic sites between conserved genes in the genome of modified vaccinia ankara (mva) vaccinia virus | |
| ES2623149T3 (es) | Parvovirus atenuado vivo | |
| Liu et al. | Development of recombinant goatpox virus expressing Echinococcus granulosus EG95 vaccine antigen | |
| Zhang et al. | Potential threat of human pathogenic orthopoxviruses to public health and control strategies | |
| Marín-López et al. | Generation of recombinant modified vaccinia virus Ankara encoding VP2, NS1, and VP7 proteins of bluetongue virus | |
| CA2372709C (en) | Vector for integration of heterologous sequences into poxviral genomes | |
| Alharbi et al. | Deletion of fifteen open reading frames from modified vaccinia virus Ankara fails to improve immunogenicity | |
| CN105879060B (zh) | 以成纤维激活蛋白α为靶点的肿瘤DNA疫苗及病毒载体疫苗 | |
| CN103298936A (zh) | 具有新型流感病毒来源的血凝素蛋白基因的重组痘苗病毒 | |
| JP5584407B2 (ja) | Ｃ型肝炎ウイルス遺伝子を有する組換えワクシニアウイルス | |
| Neckermann et al. | Transgene expression knock-down in recombinant Modified Vaccinia virus Ankara vectors improves genetic stability and sustained transgene maintenance across multiple passages | |
| CN107206035B (zh) | 丙型肝炎的治疗和/或预防用药物组合物 | |
| JP5944210B2 (ja) | 新型インフルエンザウイルス由来ヘマグルチニンタンパク質遺伝子が組み込まれたｂ５ｒ遺伝子欠損組換えワクシニアウイルス | |
| JPWO2006013815A1 (ja) | ＨＣＶウイルスタンパク質をコードするＤＮＡを保有する組換えワクチニアウイルスＤＩｓ株、およびその利用 | |
| Agaoua et al. | Synthetic Genome Shuffling of Poxviruses through Yeast for Next-Generation Oncolytic Platforms |